BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX…More brand name in Europe.
REPORT RATINGS
4.8 / 5.0 (168)
BioSpecifics Technologies Corp. reports have an aggregate usefulness score of 4.8 based on 168 reviews.